On September 10, the Meso Foundation will interview Stephen Isaacs, the chairperson, president, and CEO of Adura BioTech, during a new installment of the Foundation’s Meet the Mesothelioma Experts live broadcast. The interview will be led by the Meso Foundation’s executive director and mesothelioma expert nurse practitioner, Mary Hesdorffer, APRN.
The focus of the interview will be Audo BioTech’s experimental therapy for malignant pleural mesothelioma, known as CRS-207. CRS-207 is a weakened form of Listeria bacteria modified to reduce its ability to cause infections, but still able to stimulate the immune system.
The interview will be available live on September 10, at 1PM EST, by calling into a conference-call number. The interview is free of charge, but listeners must RSVP ahead of time by visiting curemeso.org/experts in order to receive a call-in number.
In his position at Aduro BioTech, Mr. Isaacs initiated the company’s current immunotherapy program based on attenuated strains of Listeria monocytogenes. He was responsible for recruiting key members of the current vaccine team with deep expertise in the biology of Listeria. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents.
To RSVP for the upcoming session with Stephen Isaacs or to listen to past Meet the Mesothelioma Experts sessions, visit curemeso.org/exerpts.
